Table 4.
JAG1 expression in cancer cells stratified by E‐cadherin expression (based on intensity of staining) and correlation with clinicopathologic characteristics, JAG1 expression in endothelium, and KRAS status
| Characteristics | E‐cadherin intensity (1) | P‐value | E‐cadherin intensity (2/3) | P‐value | ||||
|---|---|---|---|---|---|---|---|---|
| JAG1 | JAG1 | |||||||
| Weak | Moderate | Strong | Weak | Moderate | Strong | |||
| Total | 11 (28) | 15 (38) | 13 (33) | 40 (34) | 42 (35) | 37 (31) | ||
| Sex | 0.899 | 0.149 | ||||||
| Male | 6 (55) | 8 (53) | 8 (62) | 25 (62) | 28 (67) | 17 (46) | ||
| Female | 5 (45) | 7 (47) | 5 (38) | 15 (38) | 14 (33) | 20 (54) | ||
| Age (years) | 0.321 | 0.683 | ||||||
| <65 | 3 (27) | 8 (53) | 7 (54) | 22 (55) | 20 (48) | 21 (57) | ||
| ≥65 | 8 (73) | 7 (47) | 6 (46) | 18 (45) | 22 (52) | 16 (43) | ||
| Histologic type | 0.475 | 0.045* | ||||||
| Well differentiated | 5 (45) | 8 (53) | 4 (31) | 33 (83) | 26 (62) | 22 (59) | ||
| Others | 6 (55) | 7 (47) | 9 (69) | 7 (17) | 16 (38) | 15 (41) | ||
| T stage | 0.377 | 0.110 | ||||||
| T1, T2 | 0 (0) | 1 (7) | 0 (0) | 20 (50) | 14 (33) | 10 (28) | ||
| T3, T4 | 11 (100) | 14 (93) | 13 (100) | 20 (50) | 28 (67) | 26 (72) | ||
| Unknown | 1 | |||||||
| Lymph node metastasis | 0.480 | 0.348 | ||||||
| Negative | 5 (45) | 4 (27) | 6 (46) | 28 (70) | 24 (57) | 20 (56) | ||
| Positive | 6 (55) | 11 (73) | 7 (54) | 12 (30) | 18 (43) | 16 (44) | ||
| Unknown | 1 | |||||||
| Stage of tumor | 0.800 | 0.226 | ||||||
| 0/I/II | 3 (27) | 3 (20) | 4 (31) | 27 (68) | 23 (55) | 18 (49) | ||
| III/IV | 8 (73) | 12 (80) | 9 (69) | 13 (32) | 19 (45) | 19 (51) | ||
| Lymphatic invasion | 0.998 | 0.070 | ||||||
| Negative | 5 (45) | 7 (47) | 6 (46) | 34 (85) | 27 (64) | 25 (68) | ||
| Positive | 6 (55) | 8 (53) | 7 (54) | 6 (15) | 15 (36) | 12 (32) | ||
| Venous invasion | 0.822 | 0.724 | ||||||
| Negative | 5 (45) | 5 (33) | 5 (38) | 27 (68) | 28 (67) | 22 (59) | ||
| Positive | 6 (55) | 10 (67) | 8 (62) | 13 (32) | 14 (33) | 15 (41) | ||
| JAG1 (Endothelium) | 0.052 | <0.001** | ||||||
| Weak/moderate | 10 (91) | 10 (67) | 6 (46) | 39 (98) | 31 (74) | 19 (51) | ||
| Strong | 1 (9) | 5 (33) | 7 (54) | 1 (2) | 11 (26) | 18 (49) | ||
| KRAS status | 0.527 | 0.048* | ||||||
| Total | 6 | 8 | 9 | 12 | 22 | 21 | ||
| Wild type | 3 (50) | 5 (63) | 7 (78) | 10 (83) | 17 (77) | 11 (52) | ||
| Mutant | 3 (50) | 3 (37) | 2 (22) | 2 (17) | 5 (23) | 10 (48) | ||
| BRAF status | 0.111 | 0.863 | ||||||
| Total | 5 | 8 | 9 | 11 | 22 | 21 | ||
| Wild type | 4 (80) | 8 (100) | 6 (67) | 10 (91) | 21 (95) | 20 (95) | ||
| Mutant | 1 (20) | 0 (0) | 3 (33) | 1 (9) | 1 (5) | 1 (5) | ||
| MSI status | 0.007** | 0.977 | ||||||
| Total | 10 | 12 | 11 | 22 | 33 | 29 | ||
| MSS or MSI‐L | 10 (100) | 12 (100) | 7 (64) | 19 (86) | 29 (88) | 25 (86) | ||
| MSI‐H | 0 (0) | 0 (0) | 4 (36) | 3 (14) | 4 (12) | 4 (14) | ||
Each value is presented as number (%) of specimens. χ2‐test: *P < 0.05, **P < 0.01.